Shares of Adamas Pharmaceuticals Inc (NASDAQ:ADMS) have earned a consensus rating of “Buy” from the twelve research firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and nine have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $45.60.
Several equities analysts have recently commented on ADMS shares. Noble Financial restated a “buy” rating on shares of Adamas Pharmaceuticals in a research report on Friday, February 23rd. Cowen set a $55.00 target price on Adamas Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, December 13th. Zacks Investment Research raised Adamas Pharmaceuticals from a “hold” rating to a “buy” rating and set a $40.00 target price on the stock in a report on Wednesday, January 3rd. Piper Jaffray Companies set a $52.00 target price on Adamas Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, December 19th. Finally, BidaskClub raised Adamas Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, January 25th.
Shares of Adamas Pharmaceuticals (NASDAQ:ADMS) traded down $0.24 during trading on Friday, hitting $26.50. The stock had a trading volume of 555,305 shares, compared to its average volume of 1,109,415. Adamas Pharmaceuticals has a fifty-two week low of $13.50 and a fifty-two week high of $44.00. The stock has a market capitalization of $712.27, a P/E ratio of -6.72 and a beta of 1.59. The company has a quick ratio of 10.69, a current ratio of 10.79 and a debt-to-equity ratio of 1.55.
Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its quarterly earnings data on Thursday, February 22nd. The specialty pharmaceutical company reported ($1.27) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.18) by ($0.09). The firm had revenue of $0.57 million during the quarter, compared to analyst estimates of $0.84 million. During the same quarter last year, the firm earned ($0.68) EPS. The firm’s quarterly revenue was up 1435.1% on a year-over-year basis. analysts forecast that Adamas Pharmaceuticals will post -5.53 earnings per share for the current year.
Hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. grew its stake in shares of Adamas Pharmaceuticals by 4.0% during the second quarter. Vanguard Group Inc. now owns 745,237 shares of the specialty pharmaceutical company’s stock valued at $13,034,000 after buying an additional 28,818 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Adamas Pharmaceuticals by 11.9% during the second quarter. Dimensional Fund Advisors LP now owns 140,481 shares of the specialty pharmaceutical company’s stock valued at $2,457,000 after buying an additional 14,987 shares during the last quarter. State Street Corp grew its stake in shares of Adamas Pharmaceuticals by 9.1% during the second quarter. State Street Corp now owns 285,359 shares of the specialty pharmaceutical company’s stock valued at $4,990,000 after buying an additional 23,708 shares during the last quarter. Alps Advisors Inc. grew its stake in shares of Adamas Pharmaceuticals by 9.9% during the third quarter. Alps Advisors Inc. now owns 22,172 shares of the specialty pharmaceutical company’s stock valued at $469,000 after buying an additional 1,990 shares during the last quarter. Finally, Sei Investments Co. grew its stake in shares of Adamas Pharmaceuticals by 1,105.0% during the third quarter. Sei Investments Co. now owns 8,760 shares of the specialty pharmaceutical company’s stock valued at $185,000 after buying an additional 8,033 shares during the last quarter. 77.25% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION NOTICE: “Adamas Pharmaceuticals Inc (ADMS) Receives Average Rating of “Buy” from Analysts” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/07/adamas-pharmaceuticals-inc-adms-receives-average-rating-of-buy-from-analysts.html.
About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.